The impact will also be felt more broadly within the healthcare sector
[4] [10] These are largely mechanistic hypotheses or early findings
Collectively, these limitations underscore the need for longer-term clinical studies, human-based mechanistic investigations, and well-designed comparative analyses to more fully validate the therapeutic potential and optimize the clinical application of GLP-1RAs in liver diseases
Previous studies reporting that GLP-1-based agents suppress microglial activation, inhibit NF-B signalling, and reduce mitochondrial stress [36], further support the notion that Retatrutide may alleviate inflammatory burden, particularly through modulation of TNF-
Many discovered they were mid-protocol when coverage ended, creating an urgent need for affordable alternatives
Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial